TTY Biopharm is a Taiwan based pharmaceutical company advanced in long-acting special formulation drugs development focus on Liposomal formulation and Microsphere platform and international marketing.
Not only formulation technology, TTY Biopharm also developed Oncology and anti-critical care & Infection portfolio in Taiwan and major South-East Asian countries. Currently, TTY is a ranking number 1 domestic pharmaceutical company in hospital sector by IQVIA audit data. To support commercial, TTY Biopharm has two major manufacture sites. One of them is a dedicated cytotoxic plant and certified to meet US FDA, EMA and PMDA inspection standard for producing Oncology products. Another one is a dedicated non-cytotoxic plant and certified to meet PMDA inspection standard for non-cytotoxic products.